191 related articles for article (PubMed ID: 38287304)
21. A novel signature based on CeRNA and immune status predicts prognostic risk and drug sensitivity in gastric cancer patients.
Cao W; Zhou W; Li M; Zhang Z; Zhang X; Yang K; Yang S; Cao G; Chen B; Xiong M
Front Immunol; 2022; 13():951135. PubMed ID: 36483555
[TBL] [Abstract][Full Text] [Related]
22. Immune activity score to assess the prognosis, immunotherapy and chemotherapy response in gastric cancer and experimental validation.
Wu X; Zhou F; Cheng B; Tong G; Chen M; He L; Li Z; Yu S; Wang S; Lin L
PeerJ; 2023; 11():e16317. PubMed ID: 38025711
[TBL] [Abstract][Full Text] [Related]
23. Correlation analysis of lipid metabolism genes with the immune microenvironment in gastric cancer and the construction of a novel gene signature.
Li Y; Chen X; Zhang R; Chen M; Shen J; Wu J; Yu J; Sun Q
Clin Transl Oncol; 2023 May; 25(5):1315-1331. PubMed ID: 36520384
[TBL] [Abstract][Full Text] [Related]
24. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
Front Immunol; 2022; 13():854785. PubMed ID: 35392086
[TBL] [Abstract][Full Text] [Related]
25. Development and Validation of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and the Immune Microenvironment in Gastric Cancer.
Wang F; Chen C; Chen WP; Li ZL; Cheng H
Biomed Res Int; 2021; 2021():6014202. PubMed ID: 34708125
[TBL] [Abstract][Full Text] [Related]
26. Weighted Gene Co-expression Network Analysis Identifies a Cancer-Associated Fibroblast Signature for Predicting Prognosis and Therapeutic Responses in Gastric Cancer.
Zheng H; Liu H; Li H; Dou W; Wang X
Front Mol Biosci; 2021; 8():744677. PubMed ID: 34692770
[No Abstract] [Full Text] [Related]
27. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
28. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
Yang KS; Xu CQ; Lv J
Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
[TBL] [Abstract][Full Text] [Related]
30. Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma.
Wu Y; Ren L; Tang Y; Zhu Z; Liu S; Jiang Y; Zhang S; Zhuang X; Chen Y
Aging (Albany NY); 2023 Oct; 15(20):11588-11610. PubMed ID: 37889539
[TBL] [Abstract][Full Text] [Related]
31. The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer.
Zhao Z; Mak TK; Shi Y; Huang H; Huo M; Zhang C
Front Immunol; 2023; 14():1117255. PubMed ID: 37457685
[TBL] [Abstract][Full Text] [Related]
32. Metabolic and immune-related gene signatures: Predictive stratification and prognostic implications in gastric cancer.
Shao J; Zhang W; Li Y; Tang Y; Fan L
J Gene Med; 2024 Jan; 26(1):e3635. PubMed ID: 37984993
[TBL] [Abstract][Full Text] [Related]
33. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
Zhang C; Li D; Yu R; Li C; Song Y; Chen X; Fan Y; Liu Y; Qu X
Front Immunol; 2021; 12():651033. PubMed ID: 34054812
[TBL] [Abstract][Full Text] [Related]
34. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
[No Abstract] [Full Text] [Related]
35. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.
Zhu Y; Zhao Y; Cao Z; Chen Z; Pan W
Gene; 2022 Apr; 818():146177. PubMed ID: 35065254
[TBL] [Abstract][Full Text] [Related]
36. High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer.
Deng H; Li T; Wei F; Han W; Xu X; Zhang Y
Pathol Oncol Res; 2023; 29():1610893. PubMed ID: 36741965
[No Abstract] [Full Text] [Related]
37. Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer.
Qing X; Xu W; Liu S; Chen Z; Ye C; Zhang Y
Front Immunol; 2022; 13():843077. PubMed ID: 35273618
[TBL] [Abstract][Full Text] [Related]
38. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
[No Abstract] [Full Text] [Related]
39. Integrated analysis of 1804 samples of six centers to construct and validate a robust immune-related prognostic signature associated with stromal cell abundance in tumor microenvironment for gastric cancer.
Huo J; Guan G; Cai J; Wu L
World J Surg Oncol; 2022 Jan; 20(1):4. PubMed ID: 34983559
[TBL] [Abstract][Full Text] [Related]
40. Metabolism reprogramming signature associated with stromal cells abundance in tumor microenvironment improve prognostic risk classification for gastric cancer.
Huo J; Guan J; Li Y
BMC Gastroenterol; 2022 Jul; 22(1):364. PubMed ID: 35907819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
